1. ALLA AKTIER
  2. NYHETER
  3. 2CUREX

2cureX

Nyheter 2cureX Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to 2cureX webcast and conference call on November 24, 2022

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, will publish its Q3 2022 report on Thursday November 24, 2022 at 8:30 CET.

 
2cureX will host a webcast on the same day at 10:00 CET and present its Q3 results. After the presentation there will be a Q&A session at which 2cureX’s Executive Management will answer any questions to the Q3 reporting and to the Strategy Deep-Dive held on November 15, 2022.

To join the webcast, simply click here: https://www.2curex.com/2curex-webinar-q3-2022/

For editors and the press

For more information, please contact:

Fernando Andreu
Chief Executive Officer
fa@2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

Attachments

Invitation to 2cureX webcast and conference call on November 24, 2022

Datum 2022-11-22, kl 17:30
Källa MFN
Bifogade filer
Invitation to 2cureX webcast and conference call on November 24, 2022